. Step 21 of 41
Clinical Stem 1
Non-smoking female with a new right upper lobe lung mass and three PET-positive mediastinal lymph nodes

Question 6
To provide personalized therapy, this patient will most likely benefit from which of the following?
A. ALK-directed therapy

B. EGFR-TKI

C. Folate analogue metabolic inhibitors
incorrect correct
Each fictitious clinical case scenario is based on a conglomerate of real patient data. Cases have been modified to avoid any possibility for patient identification and to help meet educational objectives. Any resemblance to real persons, living or deceased, is purely coincidental.

The content for these webcasts has been developed by members of the World Association for Bronchology and Interventional Pulmonology. All content was reviewed by an independent multidisciplinary team of experts. Unless otherwise specified, all content is the property of WABIP.
A collaborative project with Pfizer Oncology